Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $103.67 million. The enterprise value is $100.53 million.
Market Cap | 103.67M |
Enterprise Value | 100.53M |
Important Dates
The next estimated earnings date is Tuesday, August 13, 2024, before market open.
Earnings Date | Aug 13, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 11.17 million shares outstanding. The number of shares has increased by 29.65% in one year.
Shares Outstanding | 11.17M |
Shares Change (YoY) | +29.65% |
Shares Change (QoQ) | +7.05% |
Owned by Insiders (%) | 25.20% |
Owned by Institutions (%) | 11.61% |
Float | 8.35M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.60
Current Ratio | 1.60 |
Quick Ratio | n/a |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -1,166.80%.
Return on Equity (ROE) | -1,166.80% |
Return on Assets (ROA) | -372.40% |
Return on Capital (ROIC) | n/a |
Revenue Per Employee | n/a |
Profits Per Employee | -$7.92M |
Employee Count | 6 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.25% in the last 52 weeks. The beta is 1.77, so Annovis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.77 |
52-Week Price Change | -34.25% |
50-Day Moving Average | 7.20 |
200-Day Moving Average | 9.30 |
Relative Strength Index (RSI) | 66.08 |
Average Volume (20 Days) | 2,163,028 |
Short Selling Information
The latest short interest is 1.28 million, so 11.42% of the outstanding shares have been sold short.
Short Interest | 1.28M |
Short Previous Month | 1.48M |
Short % of Shares Out | 11.42% |
Short % of Float | 15.28% |
Short Ratio (days to cover) | 3.79 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -42.88M |
Pretax Income | -47.53M |
Net Income | -47.53M |
EBITDA | -47.53M |
EBIT | -47.53M |
Earnings Per Share (EPS) | -$5.75 |
Balance Sheet
The company has $3.14 million in cash and no debt, giving a net cash position of $3.14 million or $0.28 per share.
Cash & Cash Equivalents | 3.14M |
Total Debt | n/a |
Net Cash | 3.14M |
Net Cash Per Share | $0.28 |
Equity (Book Value) | -3.35M |
Book Value Per Share | -0.30 |
Working Capital | 2.94M |
Cash Flow
Operating Cash Flow | -35.37M |
Capital Expenditures | n/a |
Free Cash Flow | -35.37M |
FCF Per Share | -$3.33 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -29.65% |
Shareholder Yield | -29.65% |
Earnings Yield | -45.85% |
FCF Yield | -34.12% |
Analyst Forecast
The average price target for Annovis Bio is $31.25, which is 236.75% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $31.25 |
Price Target Difference | 236.75% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |